About remdesivir
Antiviral nucleotide analogue
Used for
- Treats COVID-19 in eligible hospitalized patients
- May treat high-risk outpatients with early COVID-19
Usual adult dose
Intravenous infusion: 200 mg on day 1, then 100 mg once daily. Usually 5 days for hospitalized patients or 3 days for outpatients; course may be extended in some cases.
Usual dose in children
For children weighing at least 3 kg: 5 mg/kg on day 1, then 2.5 mg/kg once daily. Duration depends on clinical setting.
Common side effects
- Nausea
- Increased liver enzymes
- Infusion-related reactions
- Slow heartbeat
Important warnings
- Check liver tests before and during treatment; liver injury can occur.
- Infusion reactions may include low blood pressure, rash, or breathing difficulty.
- Use requires intravenous administration by healthcare professionals.
- Dose adjustment is generally not needed for kidney impairment, including dialysis.
Pregnancy
Human pregnancy data are limited. Use when expected benefits outweigh potential risks; COVID-19 itself can pose serious pregnancy risks.
Breastfeeding
It is not known whether remdesivir passes into human milk. Consider benefits of breastfeeding and treatment needs.
Interactions
- Chloroquine or hydroxychloroquine may reduce remdesivir activity.
- Strong enzyme inducers such as rifampin may lower remdesivir exposure.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.